Samsung, Sandoz sign deal to commercialize biosimilar SB17
Published: 11 Sep. 2023, 16:28
Updated: 11 Sep. 2023, 18:05
-
- SHIN HA-NEE
- shin.hanee@joongang.co.kr
![Samsung Bioepis headquarters in Songdo, Incheon [SAMSUNG BIOEPIS]](https://koreajoongangdaily.joins.com/data/photo/2023/09/11/4fa360af-6cdd-4f39-9dc6-feff8f1ee614.jpg)
Samsung Bioepis headquarters in Songdo, Incheon [SAMSUNG BIOEPIS]
Samsung Bioepis signed an agreement with Switzerland’s Sandoz for the sales of its Stelara biosimilar drug in the North American and European regions.
Samsung Bioepis’ SB17, a proposed biosimilar to Janssen Pharmaceuticals’ blockbuster psoriasis treatment Stelara, is the Incheon-based biopharmaceutical company’s fourth biosimilar candidate in the immunology pipeline.
In March, the company presented its Phase 1 clinical study results for SB17. Phase 3 was completed in December last year.
Stelara is the brand name for the ustekinumab drug. The global ustekinumab market size reached $17.7 billion in 2022, according to market tracker Iqvia.
BY SHIN HA-NEE [shin.hanee@joongang.co.kr]
with the Korea JoongAng Daily
To write comments, please log in to one of the accounts.
Standards Board Policy (0/250자)